have are everyone. safe many have is We everyone. This of we been you're areas environment COVID-XX impact meaningful day, and the progress challenging We've navigating the advancements. good and a where making hope direct Chris, executing you, for while been well. we Thank making and in control, Yes, pandemic.
Houston our begin in TCR-T MD strides our alongside Anderson increase we footprint me laboratory expanded infrastructure to campus our making our MD Houston, internal our program let from leasing great where program ZIOPHARM Anderson. expeditiously presence. Beauty from with has First, to progress are Sleeping facilities
of T-cells, personnel, ancillary growth skilled the studies, bioinformatics, grade clinical as genetic specializing in areas manufacturing highly modification have and and T-cells, correlative primary development, of We hired such services. process
optimizing functionality. next-generation science programs T-cell posed T-cell TCR tumor is to in cytokine combining documents, our intended on and team support behind increase investigating challenges data regulatory with technologies as been scenes, team biology. microenvironment the today's working by and as Our next Also, for the establishing to generational has biology overcome well assembling of foundational
identification, an for T-cell TCR. We and have a important and program is identifies built or in neoantigen human of group receptor use part the formidable TCR-T our of characterizes bioinformatics that program. supportive a Manufacturing
a building ZIOPHARM are only We clinical and the CPU supply manufacturing. chain, production uncertainties pilot not This in insulate our in future new the clinical of testing to provide ideas also approach to setting. to from accelerate the facility or but may unit backup facilitate outsourced helps
using on MD are campus next of will timelines. with clinical of We Anderson current compliance only manufacturing in for support small year a and manufacturing our practices the portion good our and be existing it footprint ready expect
first quarter human this trial as Also the the from immune next previously process. the the mentioned to mutation prioritized ZIOPHARM pre-IND patients to on of disclosed anticipate that are in for we trial has plus file preparing library prepare abetted in before, that be can based together hotspot year XX combinations. our And track We year. we contains receptors through HLA team the To XX from continue the and this mid-XXXX. which IND for TCRs treating unique has treat information our earlier curated on received as already FDA this TCR-T for submission
for the mutations clinical have importance These and launch we'll subset be patients TPXX to recognized with, clinically cholangiocarcinoma, evaluating common with genes to sufficient our hotspot genes advanced have colorectal, cancers. first fundamental that lung pancreatic And and cell formation a non-small KRAS begin of TCRs program. two growth TCR-T We to gynecologic, and in malignancies.
of typically are tumors. highly amino in substitutions For example, prevalent Dominant single differentiation, promotes and KRAS cell survival. acid cancerous KRAS proliferation mutations
while the us technologies target GXXC small we neoantigen We anti-cancer how can vulnerability only that mutations KRAS. variant, include a other have result molecule that the mutations. changes seen targeting allow of other identify to well that data hunting TCR-T the library recent GXXC KRAS, recognized so TCR building GXXC, our KRAS to library are Thus of variant well bodes biology tumors to approach. KRAS called and responses as small as can in targets genetic ZIOPHARM TCR for and molecules
addition targeting genes mutated is to cell targeting a is it as most considered among and ZIOPHARM transcription driver KRAS, also in stabilize the factor TPXX regulate another genomes. as In to cancers, division functions the human mutation.
trial our to TCR of draw and which our clinical well for this neoantigen pre-identified library and every these on technologies type target and Our this of will is in TCRs mutations, library to gene a assemble future neoantigen cleared has hunting cancer. almost in genetically we After can enabled rapid matching the HLA. shared have trial, mutations TCRs as us TPXX the altered with screening bodes from that with that based TCR-T the be of enrollment library targets from IND the recognize patients for
positions. top multiple cancer the nation's from of with cancer types patients occurring be multiple one support of will We centers at
We TCRs essence conducting treating five under multiple trial with one are protocol. in a clinical indications
for Simply we is our in continue on grows the we number the through team. the the targeted this prospective library greater to increase HLA and mutations TCR as Indeed, use, of licensing to quarter in-house TCRs discovery just past in clinical available of chance the for own TCR advantage available of Our patients with expanded us larger library. the our a is put number matching the cancer. use the
most is efficiently This cancer we online multiple to in unique cancers. cancer personalized head-off, trials. antigens to patient's bring targets address mutations as to further continues applicable their individual personalized give epithelial mixture. the patient's advantage unique This mutations we rise than target in need And each Our TCR-T neoantigen shared rather to the neoantigens. technology approach
with by our one screening the neoantigen. personalized one a the than the for launching TCR-T We from our more personalized patients will to as specificity, more than TCR-T with opportunity library plan address trial a the T-cell With TCR with this in treat layering to off as after capability trial administer rapidly initiating approach. library, well
plus dates of of program our to requires To With partner. the and types excited tremendous TCR-T to resourceful, fortunate a begin And time, and multiple former infrastructure to potential build expertise requires been gene speed, genetically T-cells worked internal careful of the working doing and our this to one cell never program. I've out for that the knowhow for our with and planning that with quickly split and in treat group can XX of majority And of work competent, the therapy. modified the TRCT-T have support are a they tumors patients, solid up focused potential about that of appreciate so breadth our in expertise all to years. I'm the is in on execution patients.
other to IND filing were licensing ZIOPHARM which a rapid up to years, of progress, timeline that this achieve from TCRs proud are We are compared tracking programs able the about stacks cell NCI. TCR in guide two to thanks to corporate well we a to companies. or licensing have well to internal team therapy Dr. He been the and National from of helping his as library. Rosenberg for to available unwavering Institute support ZIOPHARM they Steven creation in our is the as Cancer at can We
advance October partner separated that after and Agreement, our we will reliant in TCR-T the a were and Development capabilities corporate NCI through from You to Cooperative XXXX or the former CRADA. program had limited recall ZIOPHARM Research on
progress internal commercialize are our TCR-T to of This longer believes Thus, this the direction Dr. he and the Sleeping first trial the We reiterates patient trial. the my building hones timing is since the be important to to his while that first TCR-T grateful guided in Beauty we've to the market and of been as on dosing This NCI, capabilities XXXX is the have dependent with when are on trial on NCI. the the they program platform Dr. able non-viral will Beauty and on the that we program. excitement to note early treat them TCR-T patient NCI we his will program. Sleeping TCR-T no the out make the conversations of he the personalized on first Rosenberg, year. Rosenberg potential under occur at In about next own
generate and to the the of to NCI We authenticated T-cells they already repeating this modified engineering their are in GMP technology methodology facility. Sleeping the have in completed runs the process Beauty runs diaphragms of and back transfer have
patients. of at changes dependent of However, the a Institutes the availability the significantly patient review treatment is Health on of the National and first regulatory
the solid impact While to will depleted to ability TCR ongoing with slower of to are eligible of COVID-XX. Dr. was patients than that the Rosenberg's the enroll a wings NCI’s taking is team we There is the But believe TCR-T shutdown. is that in The any patients queue replenish prospective the for pandemic be treatment. toll, could few a identifying working tumors which sadly to patients before unfortunately trial. pace potential recipients of due
In as or cells address Eden specific day, or transfer. produced cells delighted CDXX to infused. a quickly insert or without the This The T cells CAR-T BioCell, cells with and transfer After that ZIOPHARM electroporation, CAR-T. CDXX the to very also which are antigen and derived of are by and the technology. its interleukin-XX. BioCell to worldwide as clinical United urgent next process the ability own the Taiwan, need This personalized progress T program, into production meet end criteria at Eden simplify XX-XX partners. infused based RPM day where our autologous year costs outside release the has active RPM completed T the receptor known Greater Beauty Eden to reported technology the of gene filing the after an reduce are manufacturing States Sleeping membrane assess venture Moving the on patient be to multiple our specific the CAR the gene is enables bound to for and and be System’s IL-XX T soon of to BioCell begun China propagate joint by body. genetically have T Therapeutics. Anderson modified helps cells by express state-of-the-art now in and chimeric genes with both we rapid here is to IND very MD need in we using the programs as safely CAR-T trial TriArm
cells BioCell Given report specific dosing the the partners of compassionate the been RPM multiple RPM to treat use. CDXX autologous T on technology, relapsed pleased peripheral of blood CAR-T patients after that malignancies patients several infused CDXX can of presence have the RPM appears promise data T the confirmed to weeks manufactured with the infusion and positive infused bound data Eden marrow cells are and These of approached modified using Initial without process. be They to and benefit CAR-T the IL-XX. with with bone membrane in toxicities. unexpected genetically support
follow-up Houston, patients in to specific derived marrow underway Asia. enroll trial. our or X that T malignancies. evaluating after transplantation Anderson with team is cells study the study patients bone relapsed The already prepared open, expressing MD in donor have the RPM At will CDXX CDXX and allogeneic and Additional for is enrollment phase in is CAR-T screening under
our the cell to and scheduled aforementioned for comprehensive of our time allow overview progress our planned be highlighting next a year to will program. which R&D is provide our speakers guest T QX day, us program We in
produce controlled our in say that I'm XX the initial all X/X may phase And of designed to UCSF and treat clinical tumors. under to trial. The study safety Reiki of interleukin-XX viral veledimex. the of in Dana-Farber trial portion Center, pleased of the three Now We pediatric IL-XX IL-XX sites, our Cancer of brain total engineered oral a the to vector to specifically patients program, dosing tolerability our to regulation is up evaluate and or are the active.
the patients the this At instrumenting the controlled conditionally rare are inject the the IL-XX IL-XX clinical to we first for ZIOPHARM’s to which on sensitive pontine investigational point powerful or virus safety in trial, treatment intrinsic During a in is obviously of cytokines. received the disease pediatric brainstem designation our critical of early quarter, glioma focused the diffuse of we partners are in deliver and DIPG. children, anatomy, order past
children treating survival as the for with no brainstem. invades are options relentlessly DIPG We their literally
and tolerability the initial We will the closely be patients. monitoring safety of
look on update study virtual the You at a see Recurrent the from Society in phase three controlled will and will to upcoming details inhibitor conference get the the month, where Glioblastoma OPDIVO an including as controls first accepted in IL-XX, us for new initial closer announce Glioblastoma. later to data Recurrent for or study with Neuro-Oncology additional at present we Libtayo this DIPG presentation SNO we abstracts plan have data without the of We combination the we two on IL-XX PD-X conference. indication,
July Christopher we company. on skill Bowden extensive refresh board of our highly development and experience quarter board of is appointment forward board process individuals, additions after the side, with for the two complement a has among of continues. refreshments, expanded firm optimal facilitate we our and since Dr. The sets board executive qualified as search. more shareholder Buchi, And Hagen. in directors, search recent following highly other non-employee James and and underway in who focused including eight the a our sharing biotech a additional ZIOPHARM operations Wong board Company space. to healthcare look to is of will the the Meeting consists directors directors national Annual of On and shareholders expertise. entrepreneur, to process success now the an have the to the been of during appointments complementary business national areas the last months, Clinical Kevin services in of best Stage corporate with independent long veteran, Building year's following utilize for of term industry additions The on Heidi finance, feedback the what continue seven
Dunn, to also additional named Dr. June, our new Roybal. Gavin Porteus, by welcoming quarter, Advisory Scientific led Board members four Barzel, Carl we and Dr. Matt the Kole Adi During
Management. with an Director, Sath relations plans announced the forward. University, afternoon, us we and Strategy senior team, as and most Chris, and of Executive Gilead also Corporate Investor and recently from positions of Novartis the week and for our He Previously, continue be this Northwestern Head Vice officer School news Sciences. the Adam Strategy We Finance and chief the for Illinois was other Alexion to Strategy Director release University Squibb. rest recruit Levy, and Adam from our Corporate medical potentially a Relations investor VP Communications. Corporate was he who In addition and we executives. Executive President, this Corporate Executive Adam and our Bristol-Myers the of Kellogg MBA Strategy joined leadership communications IR directing ZIOPHARM in prior in molecular McKinsey He earned move will and working biology of had with PhD as Company. and efforts for
chance to We the directly. are have him to from Adam? glad offer him hear and aboard you
